+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Doxorubicin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

  • PDF Icon

    Report

  • 149 Pages
  • September 2023
  • Region: Global
  • IMARC Group
  • ID: 5633187

Quick Summary:

The global doxorubicin market is rapidly progressing, becoming more critical than ever in the fight against various types of cancer. This potent chemotherapy drug, used in treating cancers including breast cancer, bladder cancer, Kaposi’s sarcoma, lymphoma, Wilms’ tumor, non-Hodgkin’s lymphoma, and acute lymphocytic leukemia, is experiencing growing demand due to the increasing prevalence of cancer and an aging global population who prefer less invasive treatment methods.

Furthermore, governments worldwide are investing heavily in clinical oncology advancements such as intravenous-free therapy and digital microfluidics for on-chip biochemical analysis. This factor coupled with their multifaceted approach towards increasing cancer treatment awareness is driving the global doxorubicin market growth. An increase in the number of mergers, acquisitions, and partnerships for further clinical trials with advanced forms of doxorubicin signals an encouraging future for the market. Together with the detailed insights provided in this report, understanding the direction and potential of the global doxorubicin market is crucial for those involved in the healthcare, pharmaceutical, and cancer treatment sectors.

The global doxorubicin market size reached US$ 1.2 Billion in 2022. Looking forward, the publisher expects the market to reach US$ 1.7 Billion by 2028, exhibiting a growth rate (CAGR) of 6.04% during 2023-2028.

Doxorubicin (DOX) is a generic medicine used in the process of chemotherapy for treating cancer. It is used as an injection solution or in lyophilized powder form to intravenously administer through peripherally inserted central line catheter (PICC) or central venous catheter (CVC). DOX is rapidly eliminated by enzymes and encounters hydrolytic degradation in plasma after intravenous administration. It is used to treat several types of cancer, including breast cancer, bladder cancer, Kaposi’s sarcoma, lymphoma, Wilms’ tumor, non-Hodgkin’s lymphoma, and acute lymphocytic leukemia.

Doxorubicin Market Trends:

The increasing prevalence of cancer is primarily driving the global doxorubicin market. This has resulted in the growing use of DOX in combination with other chemotherapeutic agents to treat a variety of carcinomas. Besides this, the rising demand for minimally invasive (MI) surgical procedures and the growing geriatric population who cannot undergo significant surgeries have led to the growing preference for DOX as part of the cancer treatment therapies. Governments of different countries are also implementing initiatives to support technological advancements in clinical oncology, including intravenous free therapy and digital microfluidics for on-chip biochemical analysis. They are also increasing awareness programs for the treatment of cancer. As a result, there has been a significant increase in the demand for DOX. Furthermore, researchers are spending a considerable amount on clinical trials to develop technologically advanced DOX formulations. Moreover, the growing number of mergers and acquisitions as well as partnerships for clinical trials with advanced forms of DOX is expected to create a positive outlook for the market in the coming years.

Key Market Segmentation:

The publisher provides an analysis of the key trends in each sub-segment of the global doxorubicin market report, along with forecasts at the global, regional and country level from 2023-2028. The report has categorized the market based on application and distribution channel.

Breakup by Application:

  • Breast Cancer
  • Ovarian Cancer
  • Multiple Myeloma
  • Kaposi Sarcoma
  • Leukemia
  • Bone Sarcoma
  • Endometrial Cancer
  • Others

Breakup by Distribution Channel:

  • Hospital and Retail Pharmacies
  • Online Stores
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Accord Healthcare Ltd. (Intas Pharmaceuticals Limited), Baxter International Inc., Cadila Pharmaceuticals, Cipla Inc., Hikma Pharmaceuticals PLC, Meiji Holdings Co. Ltd., Novartis AG and Pfizer Inc.

Key Questions Answered in This Report:

  • How has the global doxorubicin market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global doxorubicin market?
  • What are the key regional markets?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global doxorubicin market and who are the key players?
  • What is the degree of competition in the industry?
Frequently Asked Questions about the Global Doxorubicin Market

What is the estimated value of the Global Doxorubicin Market?

The Global Doxorubicin Market was estimated to be valued at $1.2 Billion in 2022.

What is the growth rate of the Global Doxorubicin Market?

The growth rate of the Global Doxorubicin Market is 6.0%, with an estimated value of $1.7 Billion by 2028.

What is the forecasted size of the Global Doxorubicin Market?

The Global Doxorubicin Market is estimated to be worth $1.7 Billion by 2028.

Who are the key companies in the Global Doxorubicin Market?

Key companies in the Global Doxorubicin Market include Accord Healthcare Ltd. (Intas Pharmaceuticals Limited), Baxter International Inc., Cadila Pharmaceuticals, Cipla Inc., Hikma Pharmaceuticals PLC, Meiji Holdings Co. Ltd., Novartis AG and Pfizer Inc..

Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Doxorubicin Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Application
6.1 Breast Cancer
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Ovarian Cancer
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Multiple Myeloma
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Kaposi Sarcoma
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Leukemia
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Bone Sarcoma
6.6.1 Market Trends
6.6.2 Market Forecast
6.7 Endometrial Cancer
6.7.1 Market Trends
6.7.2 Market Forecast
6.8 Others
6.8.1 Market Trends
6.8.2 Market Forecast
7 Market Breakup by Distribution Channel
7.1 Hospital and Retail Pharmacies
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Online Stores
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Others
7.3.1 Market Trends
7.3.2 Market Forecast
8 Market Breakup by Region
8.1 North America
8.1.1 United States
8.1.1.1 Market Trends
8.1.1.2 Market Forecast
8.1.2 Canada
8.1.2.1 Market Trends
8.1.2.2 Market Forecast
8.2 Asia-Pacific
8.2.1 China
8.2.1.1 Market Trends
8.2.1.2 Market Forecast
8.2.2 Japan
8.2.2.1 Market Trends
8.2.2.2 Market Forecast
8.2.3 India
8.2.3.1 Market Trends
8.2.3.2 Market Forecast
8.2.4 South Korea
8.2.4.1 Market Trends
8.2.4.2 Market Forecast
8.2.5 Australia
8.2.5.1 Market Trends
8.2.5.2 Market Forecast
8.2.6 Indonesia
8.2.6.1 Market Trends
8.2.6.2 Market Forecast
8.2.7 Others
8.2.7.1 Market Trends
8.2.7.2 Market Forecast
8.3 Europe
8.3.1 Germany
8.3.1.1 Market Trends
8.3.1.2 Market Forecast
8.3.2 France
8.3.2.1 Market Trends
8.3.2.2 Market Forecast
8.3.3 United Kingdom
8.3.3.1 Market Trends
8.3.3.2 Market Forecast
8.3.4 Italy
8.3.4.1 Market Trends
8.3.4.2 Market Forecast
8.3.5 Spain
8.3.5.1 Market Trends
8.3.5.2 Market Forecast
8.3.6 Russia
8.3.6.1 Market Trends
8.3.6.2 Market Forecast
8.3.7 Others
8.3.7.1 Market Trends
8.3.7.2 Market Forecast
8.4 Latin America
8.4.1 Brazil
8.4.1.1 Market Trends
8.4.1.2 Market Forecast
8.4.2 Mexico
8.4.2.1 Market Trends
8.4.2.2 Market Forecast
8.4.3 Others
8.4.3.1 Market Trends
8.4.3.2 Market Forecast
8.5 Middle East and Africa
8.5.1 Market Trends
8.5.2 Market Breakup by Country
8.5.3 Market Forecast
9 SWOT Analysis
9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
13.3.1 Accord Healthcare Ltd. (Intas Pharmaceuticals Limited)
13.3.1.1 Company Overview
13.3.1.2 Product Portfolio
13.3.2 Baxter International Inc.
13.3.2.1 Company Overview
13.3.2.2 Product Portfolio
13.3.2.3 Financials
13.3.2.4 SWOT Analysis
13.3.3 Cadila Pharmaceuticals
13.3.3.1 Company Overview
13.3.3.2 Product Portfolio
13.3.4 Cipla Inc.
13.3.4.1 Company Overview
13.3.4.2 Product Portfolio
13.3.4.3 Financials
13.3.4.4 SWOT Analysis
13.3.5 Hikma Pharmaceuticals PLC
13.3.5.1 Company Overview
13.3.5.2 Product Portfolio
13.3.6 Meiji Holdings Co. Ltd.
13.3.6.1 Company Overview
13.3.6.2 Product Portfolio
13.3.6.3 Financials
13.3.6.4 SWOT Analysis
13.3.7 Novartis AG
13.3.7.1 Company Overview
13.3.7.2 Product Portfolio
13.3.7.3 Financials
13.3.7.4 SWOT Analysis
13.3.8 Pfizer Inc.
13.3.8.1 Company Overview
13.3.8.2 Product Portfolio
13.3.8.3 Financials
13.3.8.4 SWOT Analysis

Companies Mentioned

  • Accord Healthcare Ltd. (Intas Pharmaceuticals Limited)
  • Baxter International Inc.
  • Cadila Pharmaceuticals
  • Cipla Inc.
  • Hikma Pharmaceuticals PLC
  • Meiji Holdings Co. Ltd.
  • Novartis AG
  • Pfizer Inc.

Methodology

Loading
LOADING...